Cubist Systematic Strategies, LLC Merus N.V. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$28.03 - $51.82 $360,830 - $667,078	-12,873 Reduced 10.18%	113,632 $5.12 Million
Q4 2023 Feb 14, 2024	BUY	$20.06 - $28.66 $2.54 Million - $3.63 Million	126,505 New	126,505 $3.48 Million
Q2 2023 Aug 14, 2023	BUY	$18.33 - $27.18 $357,966 - $530,798	19,529 Added 141.15%	33,365 $878,000
Q1 2023 May 15, 2023	BUY	$14.25 - $20.5 $197,163 - $283,638	13,836 New	13,836 $254,000
Q3 2022 Nov 14, 2022	BUY	$18.64 - $28.93 $149,474 - $231,989	8,019 Added 61.81%	20,993 $420,000
Q3 2022 Nov 14, 2022	BUY	$18.64 - $28.93 $149,474 - $231,989	8,019 Added 61.81%	20,993 $420,000
Q2 2022 Aug 15, 2022	BUY	$13.98 - $29.25 $171,227 - $358,254	12,248 Added 1687.05%	12,974 $294,000
Q1 2022 May 16, 2022	SELL	$23.58 - $30.91 $138,273 - $181,256	-5,864 Reduced 88.98%	726 $19,000
Q4 2021 Feb 14, 2022	BUY	$20.0 - $32.29 $131,740 - $212,694	6,587 Added 219566.67%	6,590 $210,000
Q3 2021 Nov 15, 2021	SELL	$16.48 - $27.23 $15,623 - $25,814	-948 Reduced 99.68%	3 $0
Q2 2021 Aug 16, 2021	BUY	$20.0 - $25.48 $19,020 - $24,231	951 New	951 $20,000

188

59M

345K

222K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.16B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.